Swiss startup Atlas Bio raises US$10 million for AI trial simulations
Creandum led the seed round, while a previously undisclosed US$2.5 million investment brings the company's total funding to US$12.5 million.
Atlas Bio has emerged from stealth with US$10 million in seed financing to develop artificial intelligence for simulating clinical trials. The Swiss startup plans to expand its scientific and commercial teams, further validate its platform and bring in additional enterprise clients through 2026.
Creandum led the investment, with its partner Katharina Wilhelm joining the board. Atlas Bio also disclosed an earlier US$2.5 million pre-seed round led by First Momentum Ventures and LEA Partners.
The company says its model uses roughly 2 million RNA readouts from human tissue to learn patterns of gene activity. It aims to predict individual patients' responses to drugs before Phase II trials, helping developers assess safety, potential efficacy and trial design.
Atlas Bio says its virtual trials take the form of 12-week simulation projects and allow different treatments to be tested against the same patient profile. The company is working with a top 10 global pharmaceutical company and is holding discussions with several others.
According to Atlas Bio, one client, a Basel-based biotech, has removed animal testing from a particular drug-development workflow and moved directly to human trials using its simulation results.
Simon Romanski and Sebastian Bayer founded Atlas Bio in 2024. Romanski is chief executive and Bayer is chief technology officer, while Dominik Hartl leads scientific strategy.
